A phase II trial evaluating liposomal irinotecan combined with capecitabine as second-line therapy for biliary tract cancer.
Alpha-fetoprotein-producing gastrointestinal malignancies represent a rare and aggressive subset of tumours chiefly arising in the stomach and, less commonly, the oesophagus or other segments of the ...